Check Genmab A/s market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$17.3B
EPS (TTM)
1.6833
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.73%
PE Ratio (TTM)
14.55
Industry PE ratio
16.65525641025641
P/B Ratio
14.5492
PEG Ratio
1.2318
EBITDA
1.3B
Revenue (TTM)
3.6B
Profit Margin
37.59%
Return On Equity TTM
28.12%
Track how Genmab A/s P/E has moved over time to understand its valuation trends.
Genmab A/s in the last 5 years
Lowest (3.17x)
September 30, 2020
Today (14.55x)
September 18, 2025
Industry (16.66x)
September 18, 2025
Highest (64.13x)
September 30, 2021
Today’s Price to Earnings Ratio: 14.55x
Compare market cap, revenue, PE, and other key metrics of Genmab A/s with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $17.3B | -27.4% | 14.55 | 37.59% | |
BUY | $60.5B | 241.54% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $99.3B | 45.88% | 27.56 | 31.86% | |
BUY | $60.9B | 5.45% | 14.49 | 31.37% |
The Genmab A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Genmab A/s investment value today
Current value as on today
₹1,11,976
Returns
₹11,976
(+11.98%)
Returns from Genmab A/s Stock
₹7,023 (+7.02%)
Dollar Returns*
₹4,953 (+4.95%)
Based on 31 analysts
61.29%
Buy
29.03%
Hold
9.68%
Sell
Based on 31 analysts, 61.29% of analysts recommend a 'BUY' rating for Genmab A/s. Average target price of $30.41
Get share price movements and forecasts by analysts on Genmab A/s.
What analysts predicted
7.79%UPSIDE
Target Price
$30.41
Current Price
$28.04
Analyzed by
31 Analysts
Target
$30.41
Genmab A/s target price $30.41, a slight upside of 7.79% compared to current price of $28.04. According to 31 analysts rating.
Search interest for Genmab A/s Stock has increased by 53% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:53% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 2 quarters, 195.0M → 2.12B (in $), with an average increase of 90.8% per quarter
Price Rise
In the last 1 month, GMAB stock has moved up by 19.9%
Revenue Rich
Revenue is up for the last 2 quarters, 4.93B → 5.86B (in $), with an average increase of 15.9% per quarter
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 61.2%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 134.5%
Organisation | Genmab A/s |
Headquarters | Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 |
Industry | Health Technology |
CEO | Dr. Jan G.J. van de Winkel Ph.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Rayne Waller | Executive VP & Chief Technical Operations Officer |
Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer |
Mr. Martin Schultz | Senior Director of Clinical Operations & Non-Independent Director |
Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer |
Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Experimental Medicines |
Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials & Non-Independent Director |
Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO |
Mr. Anthony Pagano CPA | Executive VP & CFO |
Mr. Christopher Cozic | Executive VP & Chief People Officer |
Mr. Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director |
Genmab A/s share price today is $28.04 as on at the close of the market. Genmab A/s share today touched a day high of $28.1 and a low of $27.95.
Genmab A/s share touched a 52 week high of $28.75 on and a 52 week low of $17.24 on . Genmab A/s stock price today i.e. is closed at $28.04,which is 2.45% down from its 52 week high and 62.69% up from its 52 week low.
Genmab A/s market capitalisation is $0.02T as on .
Indian investors can start investing in Genmab A/s (GMAB) shares with as little as ₹88.114 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Genmab A/s stock (as per the Rupee-Dollar exchange rate as on ).
Based on Genmab A/s share’s latest price of $28.04 as on September 19, 2025 at 1:29 am IST, you will get 0.3566 shares of Genmab A/s. Learn more about
fractional shares .
Genmab A/s stock has given -27.4% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?